Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
PHASE-II EVALUATION OF THIOTEPA FOR TREATMENT OF CENTRAL NERVOUS-SYSTEM TUMORS CANCER TREATMENT REPORTS Edwards, M. S., Levin, V. A., SEAGER, M. L., PISCHER, T. L., Wilson, C. B. 1979; 63 (8): 1419-1421
Abstract
Nineteen patients with primary malignant gliomas were treated with thioTEPA. It was found to be ineffective in 13 evaluable patients.
View details for Web of Science ID A1979HP23200036
View details for PubMedID 225030